Investors are again worried about a biotech bubble as biotech stocks take another big hit this week.
Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
Investors are again worried about a biotech bubble as biotech stocks take another big hit this week.
Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
Investors are again worried about a biotech bubble as biotech stocks take another big hit this week.
Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.
But this is not a biotech bubble we're seeing...
By Jim Bach, Associate Editor, Money Morning • @JimBach22 -
Last week on our roundup of the 2015 top stocks to invest in, we highlighted biotech stocks for their explosive growth in 2015 and their continued potential.
And while biotech stocks got creamed this past week. They're still among the best investments for 2015.
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
Wall Street pundits are claiming we are on the precipice of a biotech bubble because biotechnology stocks have been soaring. The Nasdaq Biotechnology Index has climbed 44% in the last year. The Nasdaq Composite and S&P 500 have climbed just 9% and 11% in the same time.
But it's the last week that has traders panicked about "bubble" territory.
From March 20 through March 26, the Nasdaq biotech index dipped 7%. The S&P biotech index dropped almost 11%.
By Ernie Tremblay, Biotech Investing Specialist, Money Morning -
Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.
But they're wrong; the market is simply in a period of adjustment.
The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.